UTRF Inventor Receives $1 Million NIH Grant
UT Graduate School of Medicine
UTRF Inventor Spotlight: Dr. Carmen Lozzio
Dr. Carmen B. Lozzio MD, FACMG has a distinguished career in genetics research, including extensive study of the K-562 cell line.
UTRF Executes Licensing Agreement with CytoSen
The University of Tennessee Research Foundation (UTRF) has entered into a licensing agreement with CytoSen Therapeutics, Inc. for commercial rights to use the K-562 cell lines to produce an innovative natural killer (NK) cell therapy that harnesses the power of a person’s own immune cells to help fight cancer. Unlike other cell therapies, this approach has the potential to be used as a treatment component for many types of cancer.